CO.DON finally saved

Investor has taken over the business operations of the biopharmacy company

27-Jan-2023 - Germany

With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation.

Symbolic image

The asset deal with Rejuvenate GmbH, a company of the American-Chinese ReLive Group, concluded in October 2022 as a result of a structured M&A process, has now been successfully completed through the fulfilment of the suspensive contractual conditions. Rejuvenate GmbH, which is now renamed into CO.DON GmbH, took over the operative business and the cooperation with business partners and customers will continue seamlessly. The former CO.DON AG executive board member, who has been leading the company through the insolvency proceedings in self-administration, has been appointed managing director of CO.DON GmbH. The remaining liquidation of CO.DON AG in the regular insolvency proceedings will be carried out by lawyer Rüdiger Wienberg, who has now been appointed insolvency administrator by the insolvency court. The asset deal was professionally accompanied by Dr. Wieselhuber & Partner GmbH under the leadership of the distressed M&A team led by Jörg Balz.

 Tilmann Bur, Managing Director of CO.DON GmbH: "Thanks to the professional support of the administrator, Mr. Rüdiger Wienberg, lawyer, and his team led by Michael Döhner, lawyer, as well as our advisors from Aderhold Rechtsanwaltsgesellschaft, led by Patrick Klawa, lawyer, and Bianca Böttcher, lawyer, the structured M&A process has now been brought to this positive conclusion. As an important and integral part of the ReLive Group, there is a clear vision for the future of CO.DON GmbH. In addition to stable growth in our existing markets, we are aiming for a strong global positioning in the field of regenerative therapies."

Dr. Zhao, Founder and CEO of ReLive: „With the acquisition of CO.DON, we are expanding our future-oriented business in the field of regenerative medicine with the only EMA-approved cell therapy product for cartilage repair. With this transaction, we are continuing our R&D and business development strategies to become a global leader in tissue engineering and regenerative medicine.”

Rüdiger Wienberg is delighted with the successful restructuring solution: "After continuing business operations since the summer of 2022, it was possible to implement a viable restructuring solution under the most difficult economic conditions together with the self-administration set up in the best possible way by the restructuring specialists from Aderhold. This not only secures the company's know-how and locations in Germany, but also saves over 90 % of the jobs. This would not have been possible without the trust of customers, employees and suppliers on the one hand and the support of the Federal Ministry for Economic Affairs and Climate Action as well as the competent state authorities in Saxony and Brandenburg on the other - I would like to express my sincere thanks to all of them," says Wienberg. At the same time, Wienberg is optimistic that "from an economic point of view, this successful restructuring will also lead to a very good economic result for CO.DON AG's creditors".

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances